ROS1- IHC in INP
D4D6 antibody (Cell Signaling Technology)
Gene rearrangements leading to ROS1 activation and overexpression are detected in 1% to 2% of people with lung adenocarcinoma. Although the frequency of these genomic aberration is low, its diagnosis offers patients with lung cancer the opportunity to receive highly effective targeted therapies.
Patients to be selected :
1-ROS1 testing on all lung adenocarcinoma patients, irrespective of clinical characteristics
2-ROS1 IHC may be used as a screening test in lung adenocarcinoma patients
-College of American Pathologists (CAP) [January 22, 2018]
-International Association for the Study of Lung Cancer (IASLC) [January 22, 2018]
-Association for Molecular Pathology (AMP) [January 22, 2018]
- Association Française d’Assurance Qualité en Anatomie Pathologique (AFAQAP) [August 2018]
This test will be covered by Pfizer and therefore will be free of charge.